Experts review expanding role of radiopharmaceuticals in metastatic castration-resistant prostate cancer

Dr. Pedro Barata and Dr. Johann De Bono open a discussion on the evolving role of radiopharmaceuticals in metastatic castration-resistant prostate cancer (mCRPC).

They describe how these agents are being incorporated into the broader treatment landscape, noting ongoing efforts to combine them with other therapies and to define optimal sequencing.

The series of episodes they reference covers topics such as combination approaches, patient selection, safety management and future directions, underscoring the growing interest in personalized radiopharmaceutical strategies for mCRPC.